March 13, 2020 / 12:17 PM / 24 days ago

BRIEF-I-Mab Announces Development Of TJM2 To Treat Cytokine Release

March 13 (Reuters) - I-Mab:

* I-MAB - ANNOUNCES DEVELOPMENT OF TJM2 TO TREAT CYTOKINE RELEASE SYNDROME ASSOCIATED WITH SEVERE & CRITICALLY-ILL PATIENTS WITH CORONAVIRUS DISEASE

* I-MAB - HAS SUCCESSFULLY COMPLETED A PHASE I SINGLE ASCENDING DOSE (SAD) STUDY OF TJM2 IN UNITED STATES

* I-MAB - PHASE I TJM2 STUDY EXHIBITED FAVORABLE SAFETY, TOLERABILITY, PK/PD, AND IMMUNOGENICITY PROFILES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below